JP2001524950A - 活性物質の制御された放出のための薬剤組成物 - Google Patents

活性物質の制御された放出のための薬剤組成物

Info

Publication number
JP2001524950A
JP2001524950A JP53995798A JP53995798A JP2001524950A JP 2001524950 A JP2001524950 A JP 2001524950A JP 53995798 A JP53995798 A JP 53995798A JP 53995798 A JP53995798 A JP 53995798A JP 2001524950 A JP2001524950 A JP 2001524950A
Authority
JP
Japan
Prior art keywords
matrix
active substance
release
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP53995798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524950A5 (https=
Inventor
ファナラ，ドメニコ
ベルウェール，モニーク
ブケール，アンヌ
デリールス，ミッシェル
Original Assignee
ユセベ，ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユセベ，ソシエテ アノニム filed Critical ユセベ，ソシエテ アノニム
Publication of JP2001524950A publication Critical patent/JP2001524950A/ja
Publication of JP2001524950A5 publication Critical patent/JP2001524950A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP53995798A 1997-03-14 1998-03-13 活性物質の制御された放出のための薬剤組成物 Ceased JP2001524950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9700225 1997-03-14
BE9700225A BE1011045A3 (fr) 1997-03-14 1997-03-14 Compositions pharmaceutiques pour la liberation controlee de substances actives.
PCT/BE1998/000033 WO1998041194A1 (fr) 1997-03-14 1998-03-13 Compositions pharmaceutiques pour la liberation controlee de substances actives

Publications (2)

Publication Number Publication Date
JP2001524950A true JP2001524950A (ja) 2001-12-04
JP2001524950A5 JP2001524950A5 (https=) 2004-10-28

Family

ID=3890403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53995798A Ceased JP2001524950A (ja) 1997-03-14 1998-03-13 活性物質の制御された放出のための薬剤組成物

Country Status (19)

Country Link
US (3) US6699502B1 (https=)
EP (1) EP1007005B1 (https=)
JP (1) JP2001524950A (https=)
KR (1) KR100500775B1 (https=)
CN (1) CN1126536C (https=)
AT (1) ATE275943T1 (https=)
AU (1) AU736052B2 (https=)
BE (1) BE1011045A3 (https=)
BR (1) BR9808239A (https=)
CA (1) CA2283133C (https=)
DE (1) DE69826290T2 (https=)
ES (1) ES2229483T3 (https=)
ID (1) ID22980A (https=)
IL (1) IL131292A (https=)
NZ (1) NZ337345A (https=)
PL (1) PL190735B1 (https=)
RO (1) RO120602B1 (https=)
RU (1) RU2179017C2 (https=)
WO (1) WO1998041194A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510639A (ja) * 2002-12-06 2006-03-30 ユセベ ファルシム ソシエテ アノニム エフレチリジン及びプソイドエフェドリンを含む錠剤
JP2009541341A (ja) * 2006-06-19 2009-11-26 エーシーシーユー−ブレイク テクノロジーズ，インク． セグメント状の薬剤の剤形
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
JP2001107258A (ja) * 1999-10-06 2001-04-17 Hitachi Ltd 無電解銅めっき方法とめっき装置および多層配線基板
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) * 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
DE60232445D1 (de) 2001-06-28 2009-07-09 Ucb Farchim Sa Cetirizin und pseudoephedrin enthaltende tablette
CA2451519C (en) * 2001-06-28 2007-11-06 Ucb, Farchim, S.A. Tablet comprising cetirizine and pseudoephedrine
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
ES2285088T3 (es) * 2002-01-09 2007-11-16 Ucb Farchim S.A. Composiciones farmaceuticas de liberacion modificada.
WO2003084511A1 (en) * 2002-04-04 2003-10-16 Pfizer Products Inc. Palatable chewable tablet
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
KR20080030546A (ko) * 2005-07-26 2008-04-04 유씨비 파마, 에스.에이. 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법
DK1940467T3 (da) 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
CN101252932B (zh) * 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
EP1991207A2 (en) * 2006-01-21 2008-11-19 Abbott GmbH & Co. KG Dosage form and method for the delivery of drugs of abuse
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP5597394B2 (ja) 2006-09-25 2014-10-01 コーニンクレッカ フィリップス エヌ ヴェ 回転ｘ線撮像における完全軌道に対する対象物の移動
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2010510320A (ja) 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
KR20100069685A (ko) * 2007-10-16 2010-06-24 라보팜 인코포레이트 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물
EP2217279B1 (en) * 2007-11-21 2017-11-01 The Procter & Gamble Company Preparations useful for treatment of cough
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
CA2899492C (en) 2013-02-13 2019-09-17 The Procter & Gamble Company Anise flavored medication
KR102070076B1 (ko) * 2013-05-03 2020-01-29 주식회사 제닉 탄산 함유 입자를 포함하는 필름
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
SG11201607511WA (en) 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
RU2687715C1 (ru) * 2018-05-07 2019-05-15 Федеральное государственное бюджетное учреждение науки Институт горного дела Дальневосточного отделения Российской академии наук Способ комбинированной разработки россыпных месторождений золота
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR102073185B1 (ko) * 2019-07-16 2020-02-04 (주)위바이오트리 활성성분을 포함하는 변성 다중층 수산화물 구조체를 포함하는 금속 수산화물 복합체 및 이의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477033A (en) * 1892-06-14 Bicycle
US4684516A (en) 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3681348D1 (de) 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
DE3524572A1 (de) 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5411748A (en) 1992-10-22 1995-05-02 Song Moon K Prostate extract supplemented with zinc
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
AU697456B2 (en) * 1994-06-15 1998-10-08 Dumex-Alpharma A/S Pellets
RU2065299C1 (ru) * 1994-07-15 1996-08-20 Акционерное общество закрытого типа "Олвик" Ноотропное и транквилизирующее средство
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
EP0951279A1 (en) * 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
JP2006510639A (ja) * 2002-12-06 2006-03-30 ユセベ ファルシム ソシエテ アノニム エフレチリジン及びプソイドエフェドリンを含む錠剤
JP2009541341A (ja) * 2006-06-19 2009-11-26 エーシーシーユー−ブレイク テクノロジーズ，インク． セグメント状の薬剤の剤形

Also Published As

Publication number Publication date
EP1007005A1 (fr) 2000-06-14
AU6387398A (en) 1998-10-12
KR100500775B1 (ko) 2005-07-12
DE69826290D1 (de) 2004-10-21
HK1026152A1 (en) 2000-12-08
ATE275943T1 (de) 2004-10-15
CA2283133C (fr) 2006-07-25
ES2229483T3 (es) 2005-04-16
DE69826290T2 (de) 2005-02-17
EP1007005B1 (fr) 2004-09-15
CN1250371A (zh) 2000-04-12
KR20000076269A (ko) 2000-12-26
US20020110596A1 (en) 2002-08-15
WO1998041194A1 (fr) 1998-09-24
CN1126536C (zh) 2003-11-05
BE1011045A3 (fr) 1999-04-06
RU2179017C2 (ru) 2002-02-10
ID22980A (id) 1999-12-23
IL131292A (en) 2004-07-25
US7083807B2 (en) 2006-08-01
US20040086563A1 (en) 2004-05-06
IL131292A0 (en) 2001-01-28
RO120602B1 (ro) 2006-05-30
US6699502B1 (en) 2004-03-02
AU736052B2 (en) 2001-07-26
NZ337345A (en) 2000-04-28
CA2283133A1 (fr) 1998-09-24
PL335832A1 (en) 2000-05-22
BR9808239A (pt) 2000-05-16
PL190735B1 (pl) 2005-12-30

Similar Documents

Publication Publication Date Title
JP2001524950A (ja) 活性物質の制御された放出のための薬剤組成物
US5472704A (en) Pharmaceutical controlled-release composition with bioadhesive properties
CA2290966C (en) Sertraline salts and sustained-release dosage forms of sertraline
US7569612B1 (en) Methods of use of fenofibric acid
JP4744142B2 (ja) ラモトリギンを含む徐放性処方
JP2013501810A (ja) 医薬組成物
TWI483748B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
WO1996041617A1 (en) Solid pharmaceutical form for oral use
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
KR20080033354A (ko) 카르비도파 및 레보도파를 함유하는 고형의 연장 방출약학적 조성물
JP2013519726A (ja) バクロフェン療法に感受性の病状の治療方法
JP2001502671A (ja) ＨＭＧ―ＣｏＡ還元酵素阻害剤フルバスタチンの徐放性医薬組成物
WO2006119389A2 (en) Quinine-containing controlled-release formulations
WO2004024128A2 (en) Modified release ketoprofen dosage form
MXPA99008148A (en) Pharmaceutical compositions for controlled release of active substances
WO2006025029A2 (en) Extended release composition of divalproex

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080129

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080819